Working… Menu
Trial record 1 of 1 for:    NCT03460782
Previous Study | Return to List | Next Study

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03460782
Expanded Access Status : Available
First Posted : March 9, 2018
Last Update Posted : February 11, 2019
BioGene Pharmaceutical Inc.
Information provided by (Responsible Party):
Center Trials & Treatment

Tracking Information
First Submitted Date March 5, 2018
First Posted Date March 9, 2018
Last Update Posted Date February 11, 2019
Descriptive Information
Brief Title An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Official Title An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Brief Summary IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.
Detailed Description

It is not yet known which protocols are a better treatment for glioblastoma or glioma.

The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation.

Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.

Study Type Expanded Access
Expanded Access Type Individual Patients
  • Glioblastoma
  • Glioma of Brain
Intervention Biological: Ipilimumab

Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).

Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.

This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

Other Name: MDX-010
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Eligibility Criteria

Inclusion Criteria:

  • Glioblastoma.
  • Glioma Brain.
  • Male or female subjects aged ≥18 years.
  • Histopathological evidence of glioblastoma or glioma.
  • Patients still alive must provide informed consent if required by local regulations
  • Maximal tumor diameter (including residual tumor and resection cavity if subjects had tumor resection rather than only stereotactic biopsy) up to 7cm or less.
  • Karnofsky performance status (Appendix 2) of ≥60.
  • Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 0.5 cm2 and 5 unstained slides from the glioblastoma or glioma tissue specimen.
  • Not earlier than 35 days after surgery.
  • An interval of at least 2 week for stereotactic biopsy from the start of study treatment.
  • A contrast-enhanced MRI must be obtained within 7 days of the first dose of study treatment.
  • Adequate hematologic, hepatic, and renal function defined by test
  • Women must have a negative serum or urine pregnancy test before 24 hours of initiation of study drug.
  • Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal.

Women receiving ipilimumab will be instructed to adhere to contraception for a period of 35 weeks after the last dose of program.

  • Men receiving ipilimumab and who are sexually active will be instructed to adhere to contraception for a period of 39 weeks after the last dose of program.
  • Contraception is not required for men with documented vasectomy.
  • Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
  • Women must not be breastfeeding.
  • Willing to and capable of providing written informed consent prior to any program related procedures.
  • Ability and willingness to comply scheduled visits, treatment plans, laboratory tests, and other program-related procedures.

Exclusion Criteria:

  • Prior systemic treatment anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Planned participation in another study intended for therapy of glioma or glioblastoma.
  • Primary brainstem or spinal cord tumor.
  • Diffuse leptomeningeal gliomatosis.
  • Сonfirmed mutation of the IDH1/2 genes.
  • Stem or dendritic cell therapy 60 days before the program or 45 days after the last infusion of ipilimumab.
  • Systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 21 days of study drug administration.
  • Patients on a standard high-dose steroid taper after craniotomy or stereotactic biopsy may have received a higher dose of corticosteroids within 21 days of registration, however must be at a dose < 5 mg daily prednisone or bioequivalent per day within 7 days prior to initiation of study drug.
  • Patients requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses ≤ 10 mg prednisone or bioequivalent per day in the absence of active autoimmune disease.
  • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed.
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
  • Prior organ transplantation, including allogeneic stem cell transplantation.
  • Known history of, or any evidence of active, non-infectious pneumonitis within the last 5 years.
  • Known severe (NCI-CTCAE v4.03 Grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  • Unable tolerate an MRI, or have a contraindication to MRI.
  • Active infection requiring systemic therapy.
  • Positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
  • Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV antibody) indicating acute or chronic infection.
  • Vaccination within 5 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines.

ATTENTION: Seasonal influenza vaccines for injection are live attenuated vaccines, and are not allowed.

  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ NY Heart Association - CC II), or serious cardiac arrhythmia requiring medication.
  • All other unstable, severe, or chronic medical or psychiatric conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, recent (within the past year) or active suicidal idea in behavior, or laboratory abnormalities that may increase the risk associated with program or judgment of the investigator, would make the patient participation impossible.
Sexes Eligible for Study: All
Ages 18 Years to 80 Years   (Adult, Older Adult)
Contact: Daniel M Cherrett 508 786 670 ext 94
Contact: Elizabeth Wonemeyer 443 665 380
Listed Location Countries Albania,   Bosnia and Herzegovina,   Bulgaria,   Croatia,   Romania,   Russian Federation,   Serbia,   Switzerland
Removed Location Countries  
Administrative Information
NCT Number NCT03460782
Other Study ID Numbers PST-9-IP
Responsible Party Center Trials & Treatment
Study Sponsor Center Trials & Treatment
Collaborators BioGene Pharmaceutical Inc.
Investigators Not Provided
PRS Account Center Trials & Treatment
Verification Date February 2019